has sponsored live events, journal education, and internet-based CME activities and has awarded more than 80,000 hours of CME credit.Early View from The Oncologist
- Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
- Expanding beyond maximum grade: Chemotherapy toxicity over time by age and performance status in advanced non‐small cell lung cancer in CALGB 9730 (Alliance A151729)
- Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3‐TACC3 Fusion and Recurrent Glioblastoma
- Pregnancy in Women with Metastatic Sarcomas
- Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
- All in the Levels‐ Programmed Death‐Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Gastrointestinal Cancer Patients
- Tumor evolution in a patient with recurrent endometrial cancer and synchronous neuroendocrine cancer and response to checkpoint inhibitor treatment
- A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study
- Serial Assessment of Depression and Anxiety by Patients and Providers in Women Receiving Chemotherapy for Early Breast Cancer
- Regarding “The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors”